Entero Healthcare Solutions Ltd
Incorporated in 2018, Entero Healthcare
Solutions Ltd is in the business of distribution
and marketing of pharmaceutical and surgical products and allied services[1]
- Market Cap ₹ 4,849 Cr.
- Current Price ₹ 1,114
- High / Low ₹ 1,390 / 944
- Stock P/E 161
- Book Value ₹ 387
- Dividend Yield 0.00 %
- ROCE 2.26 %
- ROE 1.80 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 29.6% CAGR over last 5 years
Cons
- Stock is trading at 2.88 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has a low return on equity of 2.97% over last 3 years.
- Earnings include an other income of Rs.109 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 56 | 105 | 137 | 178 | 318 | 409 | 348 | |
| 73 | 137 | 191 | 222 | 353 | 439 | 411 | |
| Operating Profit | -17 | -32 | -54 | -44 | -34 | -30 | -63 |
| OPM % | -30% | -30% | -39% | -25% | -11% | -7% | -18% |
| 21 | 23 | 27 | 53 | 90 | 67 | 109 | |
| Interest | 1 | 2 | 5 | 11 | 22 | 2 | 5 |
| Depreciation | 4 | 7 | 9 | 10 | 9 | 9 | 12 |
| Profit before tax | -2 | -18 | -41 | -12 | 24 | 27 | 30 |
| Tax % | 0% | 0% | 0% | 0% | -58% | 28% | 11% |
| -2 | -18 | -41 | -12 | 38 | 19 | 27 | |
| EPS in Rs | -162.67 | -1,811.38 | -106.10 | -30.31 | 8.84 | 4.41 | 6.18 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 25% |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 64% |
| TTM: | -43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 3% |
| Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 | 44 |
| Reserves | -13 | -31 | -72 | -84 | 1,583 | 1,607 | 1,640 |
| 457 | 540 | 674 | 775 | 18 | 14 | 133 | |
| 21 | 23 | 47 | 68 | 125 | 139 | 342 | |
| Total Liabilities | 466 | 533 | 654 | 764 | 1,769 | 1,804 | 2,158 |
| 46 | 50 | 51 | 41 | 34 | 28 | 50 | |
| CWIP | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Investments | 38 | 39 | 39 | 41 | 41 | 277 | 825 |
| 380 | 442 | 563 | 682 | 1,694 | 1,498 | 1,283 | |
| Total Assets | 466 | 533 | 654 | 764 | 1,769 | 1,804 | 2,158 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| -52 | -68 | -45 | -57 | -76 | -109 | -60 | |
| -167 | -7 | -69 | -58 | -763 | 208 | -122 | |
| 178 | 76 | 127 | 91 | 926 | -41 | 98 | |
| Net Cash Flow | -41 | 0 | 14 | -24 | 87 | 58 | -84 |
| Free Cash Flow | -75 | -75 | -47 | -57 | -77 | -111 | -75 |
| CFO/OP | 293% | 215% | 81% | 124% | 214% | 305% | 89% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 114 | 107 | 139 | 153 | 130 | 89 | 108 |
| Inventory Days | 206 | 177 | 103 | 68 | 65 | 110 | 85 |
| Days Payable | 101 | 48 | 99 | 132 | 88 | 87 | 87 |
| Cash Conversion Cycle | 219 | 236 | 143 | 89 | 107 | 112 | 107 |
| Working Capital Days | 2,013 | 1,201 | 1,034 | 947 | 850 | 432 | 366 |
| ROCE % | -3% | -6% | -0% | 4% | 5% | 2% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Healthcare Product Manufacturer Relationships Number |
|
||||
| Number of Districts Covered Number |
|||||
| Number of Hospital Customers Number |
|||||
| Number of Retail Pharmacy Customers Number |
|||||
| Number of SKUs Handled Number |
|||||
| Number of Warehouses Number |
|||||
| Total Warehouse Area Sq. Ft. |
|||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 2 Jun
-
Clarification On Investor Queries Relating To Profit Attributable To Owners Of The Company And Minority Interest For The Quarter Ended 31St March 2026
28 May - Clarifies Q4 FY26 profit was hit by INR 114 million one-off costs and Anand Chemiceutics acquisition raised minority interest.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Entero Healthcare filed FY26 secretarial compliance report; minor prior LODR delays and fines noted.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 May - Newspaper publication for Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
26 May - Audio recording of FY26 audited results earnings call uploaded; transcript to follow.
Concalls
-
Jun 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptAI SummaryPPT
-
Mar 2024Transcript PPT
Business Overview:[1]
EHSL, a leading Healthcare Supply Chain Solutions Specialist, ranks among India’s top three healthcare product distributors by revenue, offering demand fulfillment and generation solutions to manufacturers.